Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium
Abstract Background In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer. This suggests that selenium may also be suitable for chemoprevention of recurrence. Method The SELEBLAT study opened in September 2009 and is still recruiting all patients with non-invasive transitional cell carcinoma of the bladder on TURB operation in 15 Belgian hospitals. Recruitme... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2012 |
Reihe/Periodikum: | BMC Urology, Vol 12, Iss 1, p 8 (2012) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | Selenium / Bladder cancer / Transitional Cell Carcinoma / Chemoprevention / Randomized clinical trial / Urology / Diseases of the genitourinary system. Urology / RC870-923 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26612457 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/1471-2490-12-8 |